Myriad Genetics (MYGN) Tops Q4 EPS by 4c
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $6.18 -0.16%
EPS Growth %: -220.0%
Financial Fact:
Selling, general, and administrative expense: 111.9M
Today's EPS Names:
UBAB, LOAN, FITB, More
EPS Growth %: -220.0%
Financial Fact:
Selling, general, and administrative expense: 111.9M
Today's EPS Names:
UBAB, LOAN, FITB, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of ($0.12), $0.04 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $177.8 million versus the consensus estimate of $169.47 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
- Taiwan Semi (TSM) PT Raised to $500 at DA Davidson Following Q2 Earnings, Revenue Beat
- Oppenheimer upgrades Ecolab to Outperform, sees AI growth driving upside
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
